CN115590908B - Traditional Chinese medicine composition, antibacterial spray and preparation method - Google Patents
Traditional Chinese medicine composition, antibacterial spray and preparation method Download PDFInfo
- Publication number
- CN115590908B CN115590908B CN202211275477.1A CN202211275477A CN115590908B CN 115590908 B CN115590908 B CN 115590908B CN 202211275477 A CN202211275477 A CN 202211275477A CN 115590908 B CN115590908 B CN 115590908B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 239000007921 spray Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 244000183914 Dianthus superbus Species 0.000 claims abstract description 28
- 235000013535 Dianthus superbus Nutrition 0.000 claims abstract description 28
- 240000000249 Morus alba Species 0.000 claims abstract description 28
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 28
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 28
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 27
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 25
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 25
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 25
- 235000011477 liquorice Nutrition 0.000 claims abstract description 25
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 24
- 230000029663 wound healing Effects 0.000 claims abstract description 20
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960004022 clotrimazole Drugs 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 16
- 230000001737 promoting effect Effects 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 10
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940116229 borneol Drugs 0.000 claims abstract description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 244000234609 Portulaca oleracea Species 0.000 claims abstract 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- 241001106477 Paeoniaceae Species 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 241000951473 Schizonepeta Species 0.000 claims description 19
- 239000012153 distilled water Substances 0.000 claims description 11
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 229960004756 ethanol Drugs 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 229960004063 propylene glycol Drugs 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 35
- 229940079593 drug Drugs 0.000 abstract description 30
- 206010052428 Wound Diseases 0.000 abstract description 9
- 208000027418 Wounds and injury Diseases 0.000 abstract description 9
- 230000035876 healing Effects 0.000 abstract description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract description 5
- 208000010484 vulvovaginitis Diseases 0.000 abstract description 5
- 230000000843 anti-fungal effect Effects 0.000 abstract description 4
- 229940121375 antifungal agent Drugs 0.000 abstract description 4
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 47
- 241000219304 Portulacaceae Species 0.000 description 23
- 239000013641 positive control Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241000222122 Candida albicans Species 0.000 description 9
- 229940095731 candida albicans Drugs 0.000 description 9
- 210000001215 vagina Anatomy 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 7
- 230000007803 itching Effects 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 208000027744 congestion Diseases 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000003756 cervix mucus Anatomy 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000008350 Pruritus Vulvae Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 210000000754 myometrium Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000125175 Angelica Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition, an antibacterial spray and a preparation method thereof, wherein the traditional Chinese medicine composition comprises the following components in parts by weight: 12-18 parts of purslane, 8-12 parts of red paeony root, 8-12 parts of mulberry leaf, 6-9 parts of herba schizonepetae, 10-15 parts of fringed pink, 2-4 parts of liquorice and 2-4 parts of Chinese angelica; the antibacterial spray comprises, by mass, 5-8% of the traditional Chinese medicine composition, 0.5-1.5% of clotrimazole, 0.1-0.5% of borneol and the balance of auxiliary materials. The traditional Chinese medicine composition provided by the invention has reasonable compatibility, and has good antibacterial and anti-bacterial properties and wound healing promoting properties due to the cooperation of seven medicines. The antibacterial spray is prepared by combining traditional Chinese medicine components and broad-spectrum antifungal medicines, has remarkable effect of treating candida vulvovaginitis, has cure rate of 78.33%, and has the effects of consolidating curative effects and reducing recurrence; meanwhile, compared with the single use of the traditional Chinese medicine composition, the antibacterial spray has better treatment effect on promoting the healing of wounds.
Description
Technical Field
The invention relates to the field of personal care and medical supplies, in particular to a traditional Chinese medicine composition, an antibacterial spray and a preparation method thereof.
Background
Candida vulvovaginitis is a common and frequently-occurring disease of gynecology and is mainly caused by candida albicans, and clinically mainly appears as pruritus vulvae, burning sensation, increased leucorrhea, thickened leucorrhea which is in a curd or bean curd residue shape, and can also be accompanied with frequent urination, painful urination and dyspareunia. This is one of the most commonly affected diseases in adult females and belongs to the categories of "under-the-belt" and "pruritus vulvae" in TCM.
In recent years, reproductive health of men and women has become a focus of public attention, and various gynecological antibacterial products are developed in the market successively, and are popular with consumers. In order to seek out medicines with quick effect, small irritation and small side effect, researchers have carried out a great deal of research on the medicines, but the single use of Chinese herbal medicines mostly cannot achieve very high curative effect and has recurrent problems.
The inventor discovers that a traditional Chinese medicine composition has good antibacterial and bactericidal performance through researches in recent years, and can improve the curative effect, reduce side effects, consolidate the curative effect and reduce relapse through combining the traditional Chinese medicine and western medicine with antifungal medicines to treat candida vulvovaginitis.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a traditional Chinese medicine composition, an antibacterial spray and a preparation method thereof, so as to solve the problems in the technical background.
In order to achieve the above object, the present invention is realized by the following technical scheme:
on the one hand, the invention provides a traditional Chinese medicine composition, which comprises the following components in parts by weight: 12-18 parts of purslane, 8-12 parts of red paeony root, 8-12 parts of mulberry leaf, 6-9 parts of herba schizonepetae, 10-15 parts of fringed pink, 2-4 parts of liquorice and 2-4 parts of Chinese angelica.
In the technical scheme, the composition comprises the following components in parts by weight: 15 parts of purslane, 10 parts of red paeony root, 10 parts of mulberry leaf, 8 parts of schizonepeta, 12 parts of fringed pink, 3 parts of liquorice and 3 parts of Chinese angelica.
In the technical scheme, the traditional Chinese medicine composition is a concentrated solution which is obtained by mixing the contained components in proportion, extracting with water, and concentrating 1-2 g/ml.
In the formula, purslane has the effects of clearing heat and detoxicating, red paeony root has the effects of clearing heat and relieving pain and cooling blood and removing blood stasis, and the two medicines are compatible and used as monarch medicines; mulberry leaf and schizonepeta have the effects of dispelling wind and relieving itching, and are jointly ministerial drugs; the fringed pink is used as an adjuvant drug for clearing heat and eliminating dampness; glycyrrhrizae radix and radix Angelicae sinensis are used as guiding drug for nourishing blood, promoting blood circulation, warming channel and dredging collaterals. The seven medicines cooperate to show strict and proper compatibility of the formula. The composition has the functions of clearing heat, eliminating dampness, killing parasites, relieving itching, astringing and stopping leukorrhagia.
On the other hand, the invention also provides an antibacterial spray, which comprises 5-8% of the traditional Chinese medicine composition according to any one of claims 1-3, 0.5-1.5% of clotrimazole, 0.1-0.5% of borneol and the balance of auxiliary materials according to mass percentage.
In the technical scheme, the auxiliary materials are polyethylene glycol 4000, propylene glycol, ethanol and distilled water.
On the other hand, the invention also provides a preparation method of the antibacterial spray, which comprises the following steps:
step one, preparation of a traditional Chinese medicine composition: weighing purslane parts, red paeony root, mulberry leaf, fineleaf schizonepeta herb, fringed pink, liquorice and Chinese angelica according to a proportion, soaking in water, decocting with 8-10 times of water for 3 times, combining the filtrates, and then shrinking to obtain 1-2 g/ml concentrated solution;
and step two, weighing clotrimazole, borneol, polyethylene glycol 4000, propylene glycol, ethanol and distilled water according to a proportion, adding the concentrated solution obtained in the step one, mixing and stirring uniformly, and filling to obtain the antibacterial spray.
One of the innovations of the invention is: the formula of the traditional Chinese medicine composition has the functions of clearing heat and detoxicating, and the red paeony root has the effects of clearing heat and relieving pain and cooling blood and removing blood stasis, and the two medicines are compatible and are monarch medicines; mulberry leaf and schizonepeta have the effects of dispelling wind and relieving itching, and are jointly ministerial drugs; the fringed pink is used as an adjuvant drug for clearing heat and eliminating dampness; glycyrrhrizae radix and radix Angelicae sinensis are used as guiding drug for nourishing blood, promoting blood circulation, warming channel and dredging collaterals. The seven medicines cooperate, so that the traditional Chinese medicine composition not only has good antibacterial performance, but also can promote wound healing.
The innovation of the invention is that: by compounding the traditional Chinese medicine composition with clotrimazole, the effect of treating candida vulvovaginitis is remarkable, the curative effect is consolidated, and the recurrence is reduced; meanwhile, the curative effect on wound healing is obviously higher than that obtained by singly using the traditional Chinese medicine composition.
Compared with the prior art, the invention has the beneficial effects that:
1. the traditional Chinese medicine composition provided by the invention has reasonable compatibility, purslane has the effects of clearing heat and detoxicating, red paeony root has the effects of clearing heat and relieving pain and cooling blood and removing stasis, and the compatibility of the two medicines is monarch medicine; mulberry leaf and schizonepeta have the effects of dispelling wind and relieving itching, and are jointly ministerial drugs; the fringed pink is used as an adjuvant drug for clearing heat and eliminating dampness; glycyrrhrizae radix and radix Angelicae sinensis are used as guiding drug for nourishing blood, promoting blood circulation, warming channel and dredging collaterals. The seven medicines cooperate to mainly treat the diseases of clearing heat and drying dampness, killing parasites and relieving itching, astringing and stopping leukorrhagia, and has good antibacterial and anti-bacterial properties and wound healing promoting properties.
2. The antibacterial spray provided by the invention combines traditional Chinese medicine components and broad-spectrum antifungal medicines, is prepared after compounding, has remarkable effect of treating candida vulvovaginitis, has a cure rate of 78.33%, and has the effects of consolidating curative effects and reducing recurrence; meanwhile, the traditional Chinese medicine component is combined with the broad-spectrum antifungal clotrimazole, and the antibacterial spray prepared after compounding has better treatment effect on promoting wound healing compared with the traditional Chinese medicine composition adopted alone.
Drawings
FIG. 1 is a bar graph of the composition of application example 1 against Candida albicans zone;
fig. 2 is a graph showing the dynamic change of the influence of the antibacterial spray on the wound healing rate in application example 4.
Detailed Description
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention. It should be noted that the following embodiments and features in the embodiments may be combined with each other without conflict. The term "parts" means any mass, which is used only to distinguish between the different components, and may be 0.1g, 1kg,1000kg, etc.
Chinese medicinal composition
Example 1
A traditional Chinese medicine composition comprises the following components in parts by weight: 12 parts of purslane, 12 parts of red paeony root, 8 parts of mulberry leaf, 9 parts of schizonepeta, 10 parts of fringed pink, 4 parts of liquorice and 4 parts of Chinese angelica.
Example 2
A traditional Chinese medicine composition comprises the following components in parts by weight: 15 parts of purslane, 10 parts of red paeony root, 10 parts of mulberry leaf, 8 parts of schizonepeta, 12 parts of fringed pink, 3 parts of liquorice and 3 parts of Chinese angelica.
Example 3
A traditional Chinese medicine composition comprises the following components in parts by weight: 18 parts of purslane, 8 parts of red paeony root, 12 parts of mulberry leaf, 6 parts of schizonepeta, 15 parts of fringed pink, 2 parts of liquorice and 2 parts of Chinese angelica.
Comparative example 1
This comparative example is similar to example 2, except that purslane was omitted, specifically: a traditional Chinese medicine composition comprises the following components in parts by weight: 10 parts of red paeony root, 10 parts of mulberry leaf, 8 parts of herba schizonepetae, 12 parts of fringed pink, 3 parts of liquorice and 3 parts of Chinese angelica.
Comparative example 2
This comparative example is similar to example 2, except that red peony root is deleted, specifically: a traditional Chinese medicine composition comprises the following components in parts by weight: 15 parts of purslane, 10 parts of mulberry leaf, 8 parts of herba schizonepetae, 12 parts of fringed pink, 3 parts of liquorice and 3 parts of Chinese angelica.
Comparative example 3
This comparative example is similar to example 2, except that the leaves of the mulberry are deleted, specifically: a traditional Chinese medicine composition comprises the following components in parts by weight: 15 parts of purslane, 10 parts of red paeony root, 8 parts of schizonepeta, 12 parts of fringed pink, 3 parts of liquorice and 3 parts of Chinese angelica.
Comparative example 4
This comparative example is similar to example 2, except that the herba Schizonepetae was deleted, specifically: a traditional Chinese medicine composition comprises the following components in parts by weight: 15 parts of purslane, 10 parts of red paeony root, 10 parts of mulberry leaf, 12 parts of fringed pink, 3 parts of liquorice and 3 parts of Chinese angelica.
Comparative example 5
This comparative example is similar to example 2, except that the fringed pink herb is deleted, specifically: a traditional Chinese medicine composition comprises the following components in parts by weight: 15 parts of purslane, 10 parts of red paeony root, 10 parts of mulberry leaf, 8 parts of schizonepeta, 3 parts of liquorice, and 3 parts of Chinese angelica.
The formulations of the traditional Chinese medicine compositions prepared by the raw materials of the examples 1-3 and the comparative examples 1-5 are shown in the table 1, and are prepared by the following methods: firstly, soaking all raw material components (the raw material formulas provided in examples 1-3 and comparative examples 1-5) in water for 0.5-1 h, decocting with 8-10 times of water for 3 times, mixing filtrates, and then shrinking to obtain 1-2 g/ml concentrated solution.
TABLE 1
Group of | Formulation of |
Example 1 | 12 parts of purslane, 12 parts of red paeony root, 8 parts of mulberry leaf, 9 parts of schizonepeta, 10 parts of fringed pink, 4 parts of liquorice and 4 parts of Chinese angelica |
Example 2 | 15 parts of purslane, 10 parts of red paeony root, 10 parts of mulberry leaf, 8 parts of schizonepeta, 12 parts of fringed pink, 3 parts of liquorice and 3 parts of Chinese angelica |
Example 3 | 18 parts of purslane, 8 parts of red paeony root, 12 parts of mulberry leaf, 6 parts of schizonepeta, 15 parts of fringed pink, 2 parts of liquorice and 2 parts of Chinese angelica |
Comparative example 1 | 10 parts of red paeony root, 10 parts of mulberry leaf, 8 parts of herba schizonepetae, 12 parts of fringed pink, 3 parts of liquorice, 3 parts of Chinese angelica |
Comparative example 2 | 15 parts of purslane, 10 parts of mulberry leaf, 8 parts of herba schizonepetae, 12 parts of fringed pink, 3 parts of liquorice, and 3 parts of Chinese angelica |
Comparative example 3 | 15 parts of purslane, 10 parts of red paeony root, 8 parts of herba schizonepetae, 12 parts of fringed pink, 3 parts of liquorice, 3 parts of Chinese angelica |
Comparative example 4 | 15 parts of purslane, 10 parts of red paeony root, 10 parts of mulberry leaf, 12 parts of fringed pink, 3 parts of liquorice, 3 parts of Chinese angelica |
Comparative example 5 | 15 parts of purslane, 10 parts of red paeony root, 10 parts of mulberry leaf, 8 parts of schizonepeta, 3 parts of liquorice, 3 parts of angelica |
Determination of bacteriostatic efficacy of the composition of application example 1
Antibacterial efficacy test: the antibacterial activity of the compositions obtained in examples 1 to 3 and comparative examples 1 to 5 against Candida albicans was tested by an oxford cup agar diffusion method; candida albicans ATCC 10231, purchased from south kyo music diagnosis biotechnology limited;
the test method comprises the following steps: setting 10 groups of experiments, namely 1 negative control group, 1 positive control group and 8 treatment groups; the negative control group is distilled water, the positive control group is bacitracin 200ug/ml, 8 treatment groups are respectively concentrated solutions obtained in examples 1-3 and comparative examples 1-5 which are diluted by 10 times for 2 g/ml; each sample was repeated 5 times, 200ul of the corresponding solution was added to each group of oxford cups, and the mixture was placed in a refrigerator at 4 ℃ for 4 hours to spread the solution, and then incubated at 37 ℃ for 16 to 18 hours, the diameter of the inhibition zone was observed and measured, and the average value of 5 times of the inhibition zone was taken, as shown in table 2 and fig. 1.
Table 2 diameter of zone of inhibition/mm for compositions against Candida albicans
Group of | Diameter of bacteriostasis ring |
Negative control group | / |
Positive control group | 16.63±0.82 a |
Example 1 | 20.93±0.94 ab |
Example 2 | 21.42±1.01 ab |
Example 3 | 21.15±0.99 ab |
Comparative example 1 | 13.54±0.85 |
Comparative example 2 | 12.05±0.78 |
Comparative example 3 | 13.41±0.87 |
Comparative example 4 | 12.85±0.77 |
Comparative example 5 | 13.07±0.69 |
Note that: a: p <0.05 compared to any of comparative examples 1-5; b: p <0.05 compared to the positive control group.
As can be seen from Table 2 and FIG. 1, the compositions obtained in examples 1-3 have good antibacterial activity against Candida albicans, and the antibacterial effect of the compositions obtained in examples 1-3 on Candida albicans is significantly higher than that of the positive control group. Meanwhile, compared with comparative examples 1-5, the antibacterial effect of the composition obtained in examples 1-3 on candida albicans is obviously improved, which proves that the synergistic effect of the components of the composition obtained in the invention improves the antibacterial performance of the composition on candida albicans. In the invention, purslane in the formula of the composition has the effects of clearing heat and detoxicating, red paeony root has the effects of clearing heat and relieving pain and cooling blood and removing blood stasis, and the two medicines are compatible and are monarch medicines; mulberry leaf and schizonepeta have the effects of dispelling wind and relieving itching, and are jointly ministerial drugs; the fringed pink is used as an adjuvant drug for clearing heat and eliminating dampness; glycyrrhrizae radix and radix Angelicae sinensis are used as guiding drug for nourishing blood, promoting blood circulation, warming channel and dredging collaterals. The seven medicines cooperate, the precise and appropriate compatibility of the prescription is reflected, and the traditional Chinese medicine composition is mainly used for clearing heat and drying dampness, killing parasites and relieving itching, astringing and stopping leukorrhagia and has good antibacterial performance.
Antibacterial spray
The embodiment 4 of the application provides an antibacterial spray, which comprises, by mass percent, 7% of the traditional Chinese medicine composition described in the embodiment 2, 1% of clotrimazole, 0.2% of borneol and the balance of auxiliary materials. Wherein the auxiliary materials are polyethylene glycol 4000, propylene glycol, ethanol and distilled water.
In this embodiment, the preparation method of the antibacterial spray includes the following steps:
step one, preparation of a traditional Chinese medicine composition: weighing purslane parts, red paeony root, mulberry leaf, fineleaf schizonepeta herb, fringed pink, liquorice and Chinese angelica according to a proportion, soaking in water, decocting with 8-10 times of water for 3 times, combining the filtrates, and then shrinking to obtain 1-2 g/ml concentrated solution;
and step two, weighing clotrimazole, borneol, polyethylene glycol 4000, propylene glycol, ethanol and distilled water according to a proportion, adding the concentrated solution obtained in the step one, mixing and stirring uniformly, and filling the mixture, wherein the specification of each bottle is 25ml, thus obtaining the antibacterial spray.
The embodiment 5 of the application provides an antibacterial spray, which comprises 5% of the traditional Chinese medicine composition described in the embodiment 2, 1.5% of clotrimazole, 0.1% of borneol and the balance of auxiliary materials in percentage by mass. Wherein the auxiliary materials are polyethylene glycol 4000, propylene glycol, ethanol and distilled water.
The embodiment 6 of the application provides an antibacterial spray, which comprises, by mass percent, 8% of the traditional Chinese medicine composition described in the embodiment 2, 0.5% of clotrimazole, 0.5% of borneol and the balance of auxiliary materials. Wherein the auxiliary materials are polyethylene glycol 4000, propylene glycol, ethanol and distilled water.
The application comparative example 6 provides an antibacterial spray, which comprises 7% of the traditional Chinese medicine composition described in the example 2 by mass percentage, and the balance of auxiliary materials. Wherein the auxiliary materials are polyethylene glycol 4000, propylene glycol, ethanol and distilled water.
The application comparative example 7 provides an antibacterial spray, which comprises 1% of clotrimazole, 0.2% of borneol and the balance of auxiliary materials according to mass percentage. Wherein the auxiliary materials are polyethylene glycol 4000, propylene glycol, ethanol and distilled water.
Application example 2 vaginal mucosa irritation test of antibacterial spray
The experimental method comprises the following steps: selecting 35 female white rabbits which are healthy, adult and unmatched, dividing the experimental animals into 7 groups, namely 1 blank control group, 1 negative control group and 5 experimental groups, wherein each group comprises 5 animals; the rabbit vaginal orifice was checked prior to dosing for secretion, congestion, edema and other damage. The rabbits were fixed on the bottom to expose the perineum and the vaginal orifice, the hose was gently inserted into the vagina after wetting, 1.5ml of the antibacterial spray obtained in the corresponding examples 4 to 6 and comparative examples 6 to 7 was slowly injected into the test group by a syringe, the catheter was withdrawn after the completion of the administration, and the administration was repeated once every 24 hours for 7 days. The negative control group was treated with physiological saline as well, and the blank group was not treated at all. 24 hours after the last administration, animals are sacrificed, the complete vagina is taken out by laparotomy, longitudinal incision is carried out, and whether congestion, edema and the like appear is observed visually for reference when pathological materials are obtained. Then the vagina is put into 10% formalin solution for fixation for more than 24 hours, tissue sections of the two ends and the center of the vagina are selected, and after HE staining, histopathological examination is carried out.
Through observation of the experimental rabbits in each group, the experimental rabbits in each group have good general conditions, clean hair color, free movement, normal diet, weight increase, no abnormal secretion in vaginal mucosa, and no symptoms such as congestion, edema, necrosis and the like during the administration period. Pathological examination shows that the morphology of the vaginal mucosa epithelial cells of the rabbits in the blank control group is not abnormal, the blood vessel expansion is not seen, the leucocyte infiltration is not seen in the myometrium and adventitia layers, and the blood vessel congestion is not seen. The vaginal mucosa epithelial cells of the rabbits in the negative control group and the experimental group are slightly damaged, and the myometrium and the adventitia are infiltrated with a small amount of white blood cells, but the phenomena of inflammatory cell infiltration and tissue cell necrosis are avoided, and the phenomenon of drug stimulation reaction is eliminated. The antibacterial spray obtained in examples 4-6 and comparative examples 6-7 has no irritation to the complete vaginal mucosa group and the damaged vaginal mucosa group of rabbits.
Application example 3 observation of curative effect of antibacterial spray for treating mycotic vaginitis
Experimental grouping: 216 patients suffering from colpitis mycotica, which are married or sexual women (except pregnant women) with the age of 25-41 years, are selected and divided into 3 treatment groups and 1 control group, wherein 60 patients in each treatment group and 36 patients in the control group; the antibacterial spray obtained in example 4, comparative example 6 and comparative example 7 was used for 3 patients in the treatment group, and clotrimazole suppository (each containing 150mg of clotrimazole in Guangzhou He Ji metric pharmaceutical factory) was used in the control group;
the experimental method comprises the following steps: after washing the vulva and vagina with 2% -3% sodium bicarbonate solution, the vagina is widened by a vaginal device, and the corresponding medicament (the antibacterial spray obtained in example 4, comparative example 6 and comparative example 7) is uniformly sprayed into the vagina, 3-5 sprays/each time, 1 time a day. After the control group irrigated the vulva and vagina, clotrimazole was embolized into the deep vagina, 1 granule each time, 1 time per night. 4. Group patients all need to receive treatment for 7 days.
After treatment, the clinical results of patients are observed, and the curative effect standard is as follows: the external appearance of the leucorrhea is normal after healing, the vaginal congestion disappears, the symptoms of pruritus vulvae, burning pain and urgent urination pain are eliminated, the vaginal secretion is checked to turn into the mold and the cleanliness is I-II degrees after stopping the medicine, and the mold is still negative after checking the vaginal secretion after the next menstrual period.
Effective leucorrhea is reduced, all accompanying symptoms are relieved, vaginal secretion is checked to turn mold into yin 5 days after stopping medicine, but the patient recurs after the next menstrual period.
The leucorrhea is abnormal in appearance, the leucorrhea amount is still as much as bean dregs or curd shape, the symptoms are not improved, and the vaginal secretion is checked to be positive after 5 days of stopping the medicine. The observation results are shown in Table 3.
TABLE 3 therapeutic Effect of antibacterial sprays on mycotic vaginitis
Group of | Number n of examples | Healing of the wound | Effective and effective | Invalidation of | Total effective rate |
Control group | 36 | 21(58.33) | 11(30.56) | 4(11.11) | 32(88.89) |
Example 4 | 60 | 47(78.33) | 13(21.67) | 0(0) | 60(100) |
Comparative example 6 | 60 | 38(63.33) | 16(26.67) | 6(10) | 54(90) |
Comparative example 7 | 60 | 29(48.33) | 20(33.33) | 11(18.33) | 49(81.67) |
As can be seen from table 3: the effective rate of the patient treated by the antibacterial spray obtained in the example 4 is 100%, and the cure rate is 78.33%; the effective rate of the patients in the control group is 88.89%, the cure rate is 58.33%, the total effective rate of the anti-bacteria spray obtained in the example 4 is obviously higher than that of the control group, and the anti-bacteria spray obtained in the example 4 has obvious curative effect; the total effective rate of the antibacterial spray obtained in the example 4 for patients treated by the antibacterial spray obtained in the comparative example 6-7 is higher than that of the antibacterial spray obtained in the comparative example 6-7, the effective rate of the antibacterial spray reaches 90%, the recovery rate is 63.33%, and the antibacterial spray obtained in the example 4 has a very remarkable effect compared with that of the comparative example 6-7, so that the antibacterial spray prepared after the traditional Chinese medicine composition and the clotrimazole are compounded has a synergistic effect.
Application example 4 test for anti-bacterial spray to promote wound healing
Experimental grouping: 50 Wistar rats weighing 180+/-20 g are bred for one week so as to adapt to new environment; the animals were divided into 3 administration groups, 1 blank control group and 1 positive control group, each group of 10 Wistar rats; the antibacterial spray obtained in example 4, comparative example 6 and comparative example 7 is adopted for 3 administration groups, the blank control group adopts conventional disinfection, and the positive control group adopts adhesive plaster;
the experimental method comprises the following steps: after one week of feeding, after anesthesia with diethyl ether, the dorsal mouse hair is removed, and a circular wound surface (to the deep fascia layer) with a diameter of 1cm is made with a tissue puncher; after the molding is successful, 3 administration groups spray the antibacterial spray obtained in the corresponding example 4, the comparative example 6 and the comparative example 7 on the wound of the molded rat respectively, wherein the spraying is 3 to 5 times, and the spraying is performed twice a day based on the skin of the wound; the blank control group is sterilized conventionally every day, 2% iodine tincture is coated, and the wound of the positive control group is coated with the adhesive plaster for generating muscle twice every day, and each time is coated with 1mm thick;
wound healing was observed n days after dosing (n=3, 5, 7, 9) and the degree of wound healing was calculated for each group of rats, with statistics shown in table 4 and fig. 2; the calculation formula of the healing degree is as follows:
wound healing degree (%) = [ (nth day wound area-initial wound area)/initial wound area ] ×100%
TABLE 4 dynamic change in wound healing Rate (%)
Group of | 3d | 5d | 7d | 9d |
Blank control group | 14.57±1.14 | 33.18±2.54 | 58.24±2.94 | 82.18±3.21 |
Positive control group | 16.54±1.26 | 40.68±2.19 a | 69.35±2.01 a | 90.12±2.92 a |
Example 4 | 17.14±1.32 | 42.94±2.63 a | 78.13±1.65 abc | 98.85±2.46 abc |
Comparative example 6 | 15.36±1.02 | 36.12±2.47 | 64.46±2.52 a | 88.41±2.13 a |
Comparative example 7 | 14.23±1.28 | 31.56±1.83 | 56.72±2.74 | 78.27±2.48 |
Note that: a: p <0.05 compared to the placebo group; b: p <0.05 compared to comparative example 1; c: p <0.05 compared to the positive control group.
As can be seen from table 4 and fig. 2, there is no obvious difference between the groups after 3d, to 5d, the positive control group and example 4 showed significantly improved healing effect compared to the blank control group, to 7d and 9d, example 4 showed significantly improved healing effect compared to the positive control group, and comparative example 6 showed significantly improved healing effect compared to the blank control group; therefore, the purslane parts, the red paeony root, the mulberry leaf, the fineleaf schizonepeta herb, the fringed pink, the liquorice and the Chinese angelica have synergistic promotion effect on wound healing of rats, can obviously promote wound healing, and simultaneously, the traditional Chinese medicine components are combined with the broad-spectrum antifungal drug clotrimazole, and compared with the traditional Chinese medicine composition adopted alone, the antibacterial spray prepared after compounding has better treatment effect on promoting wound healing.
The above examples merely illustrate specific embodiments of the invention, which are described in more detail and are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention.
Claims (6)
1. The traditional Chinese medicine composition for inhibiting bacteria and promoting wound healing is characterized by being prepared from the following raw materials in parts by weight: 12-18 parts of purslane, 8-12 parts of red paeony root, 8-12 parts of mulberry leaf, 6-9 parts of herba schizonepetae, 10-15 parts of fringed pink, 2-4 parts of liquorice and 2-4 parts of Chinese angelica.
2. The antibacterial and wound healing promoting traditional Chinese medicine composition according to claim 1 is characterized by being prepared from the following raw materials in parts by weight: 15 parts of purslane, 10 parts of red paeony root, 10 parts of mulberry leaf, 8 parts of schizonepeta, 12 parts of fringed pink, 3 parts of liquorice and 3 parts of Chinese angelica.
3. The antibacterial and wound healing promoting traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is a concentrated solution which is obtained by mixing the raw materials in proportion, extracting with water, and concentrating 1-2 g/ml.
4. The spray for inhibiting bacteria and promoting wound healing is characterized by comprising, by mass, 5-8% of the traditional Chinese medicine composition according to any one of claims 1-3, 0.5-1.5% of clotrimazole, 0.1-0.5% of borneol and the balance of auxiliary materials.
5. The antibacterial and wound healing promoting spray according to claim 4, wherein the auxiliary materials are polyethylene glycol 4000, propylene glycol, ethanol and distilled water.
6. The method for preparing the antibacterial and wound healing promoting spray according to claim 4, which is characterized by comprising the following steps:
step one, preparation of a traditional Chinese medicine composition: weighing purslane, red paeony root, mulberry leaf, fineleaf schizonepeta herb, fringed pink, liquorice and Chinese angelica according to a proportion, adding water for soaking, decocting for 3 times by 8-10 times of water, combining the filtrates, and concentrating to obtain a concentrated solution of 1-2 g/ml;
and step two, weighing clotrimazole, borneol, polyethylene glycol 4000, propylene glycol, ethanol and distilled water, adding the concentrated solution obtained in the step one, mixing and stirring uniformly, and filling to obtain the antibacterial spray.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211275477.1A CN115590908B (en) | 2022-10-18 | 2022-10-18 | Traditional Chinese medicine composition, antibacterial spray and preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211275477.1A CN115590908B (en) | 2022-10-18 | 2022-10-18 | Traditional Chinese medicine composition, antibacterial spray and preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115590908A CN115590908A (en) | 2023-01-13 |
CN115590908B true CN115590908B (en) | 2023-08-01 |
Family
ID=84848256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211275477.1A Active CN115590908B (en) | 2022-10-18 | 2022-10-18 | Traditional Chinese medicine composition, antibacterial spray and preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115590908B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101181481A (en) * | 2007-12-06 | 2008-05-21 | 张治中 | Chinese medicine preparation for curing dermatosis and preparation method thereof |
-
2022
- 2022-10-18 CN CN202211275477.1A patent/CN115590908B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN115590908A (en) | 2023-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1879831A (en) | Bacteriostatic externally applied preparation for treating gynecological inflammation and method for preparing same | |
CN106692307B (en) | Hydrogel for treating female cervical erosion and preparation method thereof | |
CN102631589B (en) | Penyanxiao enema and preparation method thereof | |
CN1679687A (en) | External-applied capsules for treating gynecopathy and preparation thereof | |
CN115590908B (en) | Traditional Chinese medicine composition, antibacterial spray and preparation method | |
CN102302505B (en) | Medicinal composition for treating pelvic inflammatory disease and application thereof | |
CN104208242B (en) | One treats prostatitic external use plaster and preparation method thereof | |
CN100434083C (en) | Medicinal use of fugu cod liver oil | |
CN105106304A (en) | Traditional Chinese medicine compound preparation for treating gynecological inflammations and preparation method thereof | |
CN102600456B (en) | Bioadhesive vaginal plug for treating vaginitis and cervicitis as well as preparation method of bioadhesive vaginal plug | |
CN104306909B (en) | Prevent and treat Chinese medicine composition of cattle uterus subinvolution and preparation method thereof | |
CN107854540B (en) | External traditional Chinese medicine formula essential oil for treating haemorrhoids | |
CN106236959A (en) | A kind of external-applied ointment treating hemorrhoid | |
CN101972451B (en) | Compound infusion preparation of Chinese herbal medicines and western medicines for treating cow hysteritis and preparation method thereof | |
CN104840699A (en) | Medicine composition for treating chronic pelvic inflammation | |
CN101391053B (en) | Traditional Chinese medicine composition for treating hemorrhoid | |
CN116898940B (en) | Traditional Chinese medicine composition for early treatment of non-lactation mastitis and preparation method thereof | |
CN102389557B (en) | Chinese medicinal composition and Chinese medicinal ball for treating uterine cancer and application thereof | |
CN102028873B (en) | Tannin berberine gel for treating cervical erosion and preparation process thereof | |
CN102988847A (en) | Medicine composition used for treating vaginitis | |
CN101773581A (en) | Medicine for treating female genitourinary system inflammation | |
CN108066570B (en) | Traditional Chinese medicine extract for diminishing inflammation and relieving pain after haemorrhoid surgery and application thereof | |
CN101062135A (en) | Chinese traditional medicine suppository for improving the life quality and the preparing method thereof | |
CN100408085C (en) | Snow lotus preparation for treating prostate disease | |
CN105395671A (en) | Lightyellow sophora root-common cnidium fruit lotion used for treating damp-heat downward flow type colpitis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230712 Address after: 212300 No.1, Hehe Road, Sanqiao Shen Village, Qu'a Street, Danyang City, Zhenjiang City, Jiangsu Province Applicant after: Jiangsu Jiadi Biological Group Co.,Ltd. Address before: 511500 No. 10-2, Guangzhou road, Guangzhou (Qingyuan) industrial transfer park, Shijiao Town, Qingcheng District, Qingyuan City, Guangdong Province Applicant before: Guangdong Hanrun Biotechnology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |